Bavarian Nordic A/S (0DPB.IL)
| Previous close | 155.77 |
| Open | 159.55 |
| Bid | 158.25 x N/A |
| Ask | 164.75 x N/A |
| Day's range | 158.35 - 162.30 |
| 52-week range | 125.55 - 221.90 |
| Volume | |
| Avg. volume | 119,350 |
| Market cap | 15.088B |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | 11.41 |
| EPS (TTM) | 14.09 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 7, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transactions concern grants of restricted stock units as part of the remuneration of the Board of Directors as adopted at the ordinary general meeting on April 16, 2024. Restricted stock units equivalent to the value of
- GlobeNewswire
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU’s capability to respond to future biological threats and emergencies by ena
- GlobeNewswire
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older. Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end o
